Search - tctmd.com

Displaying 901 - 920 of 984

Sort: Relevancy | Date

Presentation TCT 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presenter: Michael Love

October 25, 2012

Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone

October 25, 2012

Presentation TCT 2012

Ticagrelor Update: PLATO: Recent Analyses

Presenter: Robert Harrington

October 24, 2012

Presentation TCT 2012

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Presenter: C. Michael Gibson

October 24, 2012

Presentation TCT 2012

Prasugrel Update: TRILOGY

Presenter: E. Magnus Ohman

October 24, 2012

Presentation TCT 2012

Prasugrel Is the Gold Standard!

Presenter: Matthew Price

October 24, 2012

Presentation TCT 2012

GP IIb/IIIa Inhibition: New Studies, New Insights

Presenter: David Moliterno

October 24, 2012

Presentation TCT 2012

Factor IXa Inhibition (Aptamer) Update

Presenter: Roxana Mehran

October 24, 2012

Presentation TCT 2012

Clopidogrel Is Still the Choice for Most!

Presenter: Shamir Mehta

October 24, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation TCT 2012

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Presenter: Marco Valgimigli

October 24, 2012

Presentation TCT 2012

Ticagrelor Is the Right Choice: More Potent, Better Data!

Presenter: Dimitrios Alexopoulos

October 24, 2012

Presentation TCT 2012

The Longer the Better Is Still the Way to Go, at Least for Now!

Presenter: Laura Mauri

October 24, 2012

News Conference News TCT 2012

PEACE: Data Demonstrate Benefits of Plaque Identification in High-Risk Patients

October 24, 2012

News Conference News TCT 2012

Paradigm Shift from Ischemia to Vulnerable Plaque Needed to Prevent Sudden Coronary Death

October 24, 2012

Presentation TCT 2012

Medical Therapy During Interhospital Transport: Fibrinolytic and/or Anticoagulant?

Presenter: Frans Van de Werf

October 24, 2012

Presentation TCT 2012

Longer Is Better Is Old School Thinking!

Presenter: Marco Valgimigli

October 24, 2012

News Conference News TCT 2012

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

October 24, 2012

News Conference News TCT 2012

FAME 2: FFR-Guided PCI Cost Effective vs. Medical Therapy

October 24, 2012

Presentation TCT 2012

Cangrelor: CHAMPION PHOENIX Update

Presenter: Harvey White

October 24, 2012

Advertisement

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Ticagrelor Update: PLATO: Recent Analyses

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Prasugrel Update: TRILOGY

Prasugrel Is the Gold Standard!

GP IIb/IIIa Inhibition: New Studies, New Insights

Factor IXa Inhibition (Aptamer) Update

Clopidogrel Is Still the Choice for Most!

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Ticagrelor Is the Right Choice: More Potent, Better Data!

The Longer the Better Is Still the Way to Go, at Least for Now!

PEACE: Data Demonstrate Benefits of Plaque Identification in High-Risk Patients

Paradigm Shift from Ischemia to Vulnerable Plaque Needed to Prevent Sudden Coronary Death

Medical Therapy During Interhospital Transport: Fibrinolytic and/or Anticoagulant?

Longer Is Better Is Old School Thinking!

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

FAME 2: FFR-Guided PCI Cost Effective vs. Medical Therapy

Cangrelor: CHAMPION PHOENIX Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content